1. Enhanced: The Need for a Global HIV Vaccine Enterprise
- Author
-
Andrew J. McMichael, David Baltimore, Michel Kazatchkine, Edmund C. Tramont, M. W. Makgoba, Richard D. Klausner, Chris Collins, Helene D Gayle, Nirmal Kumar Ganguly, Harold E. Varmus, Julie L. Gerberding, Margaret I. Johnston, Anthony S. Fauci, Seth Berkley, Judith N. Wasserheit, Giuseppe Pantaleo, R. Gordon Douglas, Peter Piot, Barton F. Haynes, José Esparza, Yiming Shao, Lawrence Corey, Donald P. Francis, and Gary J. Nabel
- Subjects
Clinical trial ,Multidisciplinary ,Knowledge management ,business.industry ,Collaborative model ,Nanotechnology ,HIV vaccine ,business ,Pace - Abstract
A new collaborative model of research is needed to increase resources, to prioritize the RD (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.
- Published
- 2003